A comparative analysis of clinicopathological factors and survival between esophageal basaloid squamous cell carcinoma and conventional esophageal squamous cell carcinoma |
| |
| Affiliation: | 1. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China;2. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China;1. Department of General, Visceral, Transplant, and Thoracic Surgery, Frankfurt University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany;2. Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany;3. Dr. Senckenberg Institute of Pathology, Frankfurt University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany;1. Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China;2. Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China;3. Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China;4. Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China;5. Department of General Surgery, People''s Hospital of Guyuan City, Ningxia, China;1. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;2. Hepatobiliary Surgery, The First Affiliated Hospital, College of Medicine, Shihezi University, Shihezi, Xinjiang, China;1. Department of Surgery - ASST Sette Laghi, Varese, Italy;2. Department of Surgery, Patel Hospital, Karachi, Pakistan;3. European School of Soft Tissue Sarcoma Surgery, ESSO, Brussels, Belgium;4. Sarcoma Service, Department of Surgery, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy;5. Midlands Abdominal and Retroperitoneal Sarcoma Unit (MARSU), Queen Elizabeth Hospital Birmingham, UK;6. Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy;7. Department of Orthopedic Surgery, ASST Monza Ospedale San Gerardo, Italy;1. The Royal Marsden Hospital NHS Foundation Trust, United Kingdom;2. The Institute of Cancer Research, United Kingdom |
| |
| Abstract: | IntroductionRecently, the number of diagnosed esophageal basaloid squamous cell carcinoma (EBSCC) has gradually increased. However, available data on EBSCC are limited to date.MethodsA total of 165 EBSCC (Cohort 1) and 515 conventional esophageal squamous cell carcinoma (ESCC) (Cohort 2) were retrospectively analyzed.ResultsIn Cohort 1, 70 cases only had invasive EBSCC component (42.4%, defined as Group 1), 73 cases had concomitant invasive ESCC component (44.2%, Group 2), and 22 had concomitant invasive poor-differentiated component (13.3%, Group 3). Lymph node metastasis rates of Group 3, Group 2 and Group 1 were ranked from high to low (P = 0.044). There were higher patient age (P = 0.047), smaller tumor size (P = 0.009), more nerve invasion (P < 0.001), and lower pTNM stage (P < 0.001) in EBSCC (Cohort 1), compared with ESCC (Cohort 2). In Cohort 1 and Cohort 2, pTNM stage was an independent prognostic factor for both DFS and OS. No significant survival difference was found between EBSCC (Cohort 1) and ESCC (Cohort 2) in pIA-B stage, pIIA-B stage, pIIIA-B stage and pIVA-B stage (P > 0.05).ConclusionOur analysis of the largest EBSCC series from a single institution to date with conventional ESCC demonstrated that EBSCC carried a similar prognosis with ESCC in pIA-B stage, pIIA-B stage, pIIIA-B stage and pIVA-B stage. And pure EBSCC, didn't have poorer survival than mixed EBSCC with concomitant ESCC or other components. Our findings may be valuable in the better understanding of EBSCC's biological behaviors, and the related molecular mechanism is needed to be explored in the future. |
| |
| Keywords: | Esophageal basaloid squamous cell carcinoma (EBSCC) pTNM stage Invasive component Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
